GleamWall
中文EN

CLRB Cellectar Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1279704 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-37.2%
TTM EPS YoY70.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-170.0%
ROA-116.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets24.6%
Debt / equity0.00x
Current ratio4.44x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$11.50M$26.14M
SG&A expense$11.48M$25.64M
Operating income-$22.98M-$51.78M
Pretax income-$21.79M-$44.52M
Income tax—$66,000
Net income-$21.79M-$44.58M
EBITDA-$22.77M-$51.49M
EPS (basic)-8.35-36.52
EPS (diluted)-8.35-41.89
Weighted avg. shares (diluted)2.61M1.24M
Balance sheet
Cash & equivalents$13.20M$23.29M
Current assets$14.04M$24.25M
PP&E, net$549,405$757,121
Total assets$14.98M$25.47M
Current liabilities$4.75M$9.39M
Total liabilities$5.06M$9.80M
Shareholders' equity$8.54M$14.29M
Shares outstanding4.24M1.54M
Cash flow statement
Operating cash flow-$23.12M-$47.58M
Capital expenditure$5,880$104,195
Free cash flow-$23.12M-$47.69M
Investing cash flow-$5,880-$104,195
Financing cash flow$13.03M$61.41M
Depreciation & amortization$213,597$291,653
Stock-based compensation$2.26M$4.27M

Free plan shows the latest 2 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.